✦ LIBER ✦

Long-term retention rate of pramipexole in the treatment of Parkinson’s disease

✍ Scribed by Tapani Keränen; Mervi Tuhkasaari; Hanna Kuusisto

Publisher: Springer
Year: 2009
Tongue: English
Weight: 60 KB
Volume: 65
Category: Article
ISSN: 0031-6970
DOI: 10.1007/s00228-009-0661-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Reply: long-term retention rate of prami

Reply: long-term retention rate of pramipexole in the treatment of Parkinson’s disease

✍ Maurits E. L. Arbouw; Kris L. L. Movig; Jeroen P. P. van Vugt; Toine C. G. Egber 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 44 KB

Pramipexole versus sertraline in the tre

Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease

✍ P. Barone; L. Scarzella; R. Marconi; A. Antonini; L. Morgante; F. Bracco; M. Zap 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 310 KB

Psychotic complications of long term lev

Psychotic complications of long term levodopa treatment of Parkinson's disease

✍ L. Rampello; R. Raffaele; P. Furnari; I. Vecchio; M. Malaguarnera 📂 Article 📅 1996 🏛 Elsevier Science 🌐 English ⚖ 297 KB

Long–term survival of Parkinson's diseas

Long–term survival of Parkinson's disease

✍ M. D'Amelio; P. Ragonese; L. Morgante; A. Reggio; G. Callari; G. Salemi; G. Save 📂 Article 📅 2005 🏛 Springer 🌐 English ⚖ 234 KB

Long-term follow-up of early dopa treatm

Long-term follow-up of early dopa treatment in Parkinson's disease

✍ Dr. Charles H. Markham; Shirley G. Diamond 📂 Article 📅 1986 🏛 John Wiley and Sons 🌐 English ⚖ 725 KB

Long-term efficacy and safety of pramipe

Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial

✍ J. Carsten Möller; Wolfgang H. Oertel; Jürgen Köster; Gianni Pezzoli; Leandro Pr 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB 👁 1 views

## Abstract A double‐blind, placebo‐controlled study with a subsequent open‐label phase was conducted in 354 patients with Parkinson's disease (PD) and motor fluctuations under individually adjusted therapy with levodopa. During the double‐blind phase 174 patients received pramipexole and 180 place